Brief: Cabaletta Bio Reports Clinical Data From The Second Dose Cohort In Descaartes Trial In Patients With MPV

Cabaletta Bio

18/08/2021 12:24

Aug 18 (Reuters) - Cabaletta Bio Inc  CABA.O :
    * CABALETTA BIO REPORTS CLINICAL DATA FROM THE SECOND DOSE
COHORT
IN DESCAARTES™ TRIAL IN PATIENTS WITH MPV
    * CABALETTA BIO - NO DOSE-LIMITING TOXICITIES OR CLINICALLY
RELEVANT ADVERSE EVENTS OBSERVED AS OF AUGUST 17 USING 100
MILLION CELLS IN SECOND DOSE COHORT
    * CABALETTA BIO INC - DSG3-CAART PERSISTENCE OBSERVED IN ALL
THREE
PATIENTS IN SECOND DOSE COHORT DURING 28 DAYS FOLLOWING INFUSION
    * CABALETTA BIO INC - DOSING INITIATED IN THIRD COHORT AT
500
MILLION CELLS
    * CABALETTA BIO INC - BIOLOGIC ACTIVITY DATA FROM FIRST TWO
DOSING
COHORTS AND THIRD COHORT SAFETY DATA ANTICIPATED IN 4Q21
    * CABALETTA BIO INC - ABSENT DLTS IN THIRD COHORT, A FOURTH
DOSE
COHORT USING 2.5 BILLION CELLS IS ALSO ANTICIPATED TO INITIATE
DOSING THIS YEAR

Source text for Eikon:  ID:nGNXbDfFzc 
Further company coverage:  CABA.O 

 ((Reuters.Briefs@thomsonreuters.com;))